Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR0N74)

Drug Name

LAM-002 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]
B-cell non-hodgkin lymphoma	2B33.5	Phase 1	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apilimod dimesylate	DM4N2O0	Non-hodgkin lymphoma	2B33.5	Phase 2	[2]
YM-201636	DMU86XT	Discovery agent	N.A.	Preclinical	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)	TTA4M1N	FYV1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02594384) A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) (LAM-002A/NHL). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	PIKfyve negatively regulates exocytosis in neurosecretory cells. J Biol Chem. 2008 Feb 1;283(5):2804-13.